Gepotidacin - GlaxoSmithKline

Drug Profile

Gepotidacin - GlaxoSmithKline

Alternative Names: 2140944; GSK 2140944; GSK-2140944E

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Acenaphthenes; Antibacterials; Aza compounds; Ketones; Piperidines; Pyridines; Pyrones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gonorrhoea; Skin and soft tissue infections
  • No development reported Respiratory tract infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Respiratory-tract-infections(In volunteers) in United Kingdom (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Respiratory-tract-infections(In volunteers) in United Kingdom (PO, Capsule)
  • 17 Oct 2017 GlaxoSmithKline completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO, Tablet) (NCT02853435)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top